Followers | 27 |
Posts | 5124 |
Boards Moderated | 0 |
Alias Born | 01/27/2014 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, January 22, 2020 7:29:34 PM
Source: GlobeNewswire Inc.
ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research has been invited to discuss the potential role of DLAs to combat high consequence biodefense and biologic threats at 2020 American Society of Microbiology (ASM) Biothreats, being held January 28 – 30, 2020 at the Hyatt Regency Crystal City in Arlington, Virginia.
Dr. Cassino’s talk, “Direct Lytic Agents: Novel Pipeline For Biothreat Defense”, will include an overview of the Company’s DLA pipeline, including agents with potential utility against biowarfare threats, such as anthrax and other weaponizable pathogens. Dr. Cassino will also discuss the potential role of the Company’s lead product candidate exebacase, currently being studied in a pivotal Phase 3 trial, in addressing the downstream threat of hospital-acquired MRSA bacteremia for a potential bio-threat exposure with mass casualty events.
Presentation Details:
Presentation Title: Direct Lytic Agents: Novel Pipeline for Biothreat Defense
Session Title: New Developments in Antimicrobials
Room: Potomac
Time and Date: Wednesday, January 29, 2020, 1:30 p.m. – 1:55 p.m. ET
A copy of the presentation will be available on the Investors & Media section of the Company’s website at www.contrafect.com.
About ContraFect:
ContraFect is a biotechnology company focused on discovering and developing differentiated biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a new class of DLAs, which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including Pseudomonas aeruginosa (P. aeruginosa), Acinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as methicillin-resistant Staph aureus (MRSA) and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S.
Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.
Forward-Looking Statements:
This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding ContraFect’s ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, statements made regarding the conference and the presentation, statements made regarding DLAs, including exebacase, and their role in bio-threats and biodefense, ContraFect’s ability to address life threatening infections using its DLA platform, whether lysins are a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether amurins exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens and whether the properties of ContraFect’s lysins and amurins will make them suitable for targeting antibiotic-resistant organisms, such as Staph aureus and P. aeruginosa. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including those detailed under the caption “Risk Factors” in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Relations Contacts:
Michael Messinger
ContraFect Corporation
Tel: 914-207-2300
Email: mmessinger@contrafect.com
Lauren Stival
Stern Investor Relations
Tel: 212-362-1200
Email: lauren.stival@sternir.com
Primary Logo
Recent CFRX News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:24:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:41:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:30:55 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/03/2023 09:08:09 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/03/2023 04:16:01 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/30/2023 09:24:34 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/24/2023 08:06:07 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/23/2023 08:05:56 PM
- ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study • GlobeNewswire Inc. • 10/16/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/29/2023 03:15:52 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/25/2023 12:00:18 PM
- ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development • GlobeNewswire Inc. • 09/19/2023 12:30:00 PM
- ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370 • GlobeNewswire Inc. • 09/18/2023 11:30:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/14/2023 08:05:49 PM
- ContraFect to Present at the World Anti-Microbial Resistance Congress 2023 • GlobeNewswire Inc. • 08/28/2023 12:00:00 PM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM